CMN-005 by CoImmune for Mantle Cell Lymphoma: Likelihood of Approval

CMN-005 is under clinical development by CoImmune and currently in Phase II for Mantle Cell Lymphoma.

Promising Debut for CRISPR Gene Editing Therapy for LDL Lowering

PHILADELPHIA — A DNA base editing therapy, intended for lifelong lowering of LDL cholesterol, passed initial tests in people with severe, advanced atherosclerotic cardiovascular disease

November 13, 2023

Clinical Challenges: Helping Patients Navigate Safety Concerns of OTC Eye Drops

Artificial tears are the mainstay of dry eye disease (DED) management, and patients typically start by using over-the-counter (OTC) drops several times a day. But

November 28, 2023

Study reveals higher post-meal insulin responses linked to lower diabetes risk over five years

Study investigated the long-term cardiometabolic effects of postprandial insulin hypersecretion in pregnant women, finding that higher insulin responses post-meals were linked to better beta-cell function

December 18, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.